Related Experiment Video

Updated: Jun 23, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Enhanced haemodynamic effects of propranolol in acute myocardial infarction

B Silke, G I Nelson, S P Verma

    European Heart Journal
    |May 1, 1984
    PubMed

    Insights

    Myocardial infarction patients exhibit heightened sympathetic activity, leading to greater hemodynamic responses to beta-blockade compared to stable angina patients. This suggests a hyperadrenergic state influences cardiac beta-adrenoceptor function.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Physiology

    Background:

    • Sympathetic activation is implicated in myocardial infarction (MI).
    • The hemodynamic effects of beta-blockade may differ in MI patients due to this activation.

    Purpose of the Study:

    • To assess the influence of sympathetic activation on hemodynamic responses to intravenous beta-blockade.
    • To compare the dose-response characteristics of propranolol in patients post-MI versus stable angina.

    Main Methods:

    • Eight patients with uncomplicated MI and eight with stable angina received escalating intravenous propranolol doses (2, 4, 8 mg).
    • Hemodynamic variables, including cardiac output and systemic blood pressure, were monitored.
    • Left ventricular filling pressure was also assessed.

    Main Results:

    • Propranolol caused dose-related decreases in cardiac output and systemic blood pressure in MI patients, more pronounced than in stable angina patients.
    • Despite greater cardiac output reduction in MI, left ventricular filling pressure increased less compared to stable angina.
    • These findings suggest increased left ventricular compliance in MI patients under high sympathetic stimulation.

    Conclusions:

    • The hyperadrenergic state in myocardial infarction potentiates hemodynamic responses to beta-blockade.
    • Increased left ventricular compliance may mitigate the rise in filling pressure despite greater cardiac depression.
    • These results support the role of sympathetic activation in modulating cardiac beta-adrenoceptor function post-MI.

    More Related Videos

    Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine12:37

    Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

    Published on: February 9, 2016

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

    Published on: April 17, 2021

    Related Concept Videos

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
    Antihypertensive Drugs: Types of β-Blockers01:28

    Antihypertensive Drugs: Types of β-Blockers

    β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...